KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Beginning Cash Balance: 2017-2025

Historic Beginning Cash Balance for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $60.5 million.

  • Aquestive Therapeutics' Beginning Cash Balance fell 32.64% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 212.61%. This contributed to the annual value of $23.9 million for FY2024, which is 12.47% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Beginning Cash Balance stood at $60.5 million for Q3 2025, which was down 11.83% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Beginning Cash Balance ranged from a high of $95.2 million in Q2 2024 and a low of $14.7 million during Q2 2022.
  • For the 3-year period, Aquestive Therapeutics' Beginning Cash Balance averaged around $53.6 million, with its median value being $60.5 million (2025).
  • In the last 5 years, Aquestive Therapeutics' Beginning Cash Balance tumbled by 48.31% in 2022 and then skyrocketed by 300.56% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Beginning Cash Balance (Quarterly) stood at $31.2 million in 2021, then tumbled by 40.16% to $18.6 million in 2022, then soared by 33.61% to $24.9 million in 2023, then soared by 212.61% to $77.9 million in 2024, then tumbled by 32.64% to $60.5 million in 2025.
  • Its Beginning Cash Balance was $60.5 million in Q3 2025, compared to $68.7 million in Q2 2025 and $71.5 million in Q1 2025.